

- Dudek AM, Grotenhuis AJ, Vermeulen SH, et al. Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? *Int J Mol Sci* 2013;14:12346–12366.
- Chang DW, Gu J, Wu X. Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. *Urol Oncol* 2012;30:524–532.
- Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. *Am J Pathol* 2001;158:1955–1959.
- Ornitz DM, Itoh N. Fibroblast growth factors. *Genome Biol* 2001;2.
- van Rhijn BWG, Montironi R, Zwarthoff EC, et al. Frequent FGFR3 mutations in urothelial papilloma. *J Pathol* 2002;198:245–251.
- Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. *J Pathol* 2007;213:91–98.
- Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. *Cancer Res* 2009;69:8472–8481.
- Sayan AE, D'Angelo B, Sayan BS, et al. p73 and p63 regulate the expression of fibroblast growth factor receptor 3. *Biochem Biophys Res Commun* 2010;394:824–828.
- di Martino E, L'Hôte CG, Kennedy W, et al. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. *Oncogene* 2009;28:4306–4316.
- Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. *Hum Mol Genet* 2012.
- Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. *Pharm Res* 2006;23:1324–1331.
- Yoshimura K, Eto H, Miyake H, et al. Messenger ribonucleic acids for fibroblast growth factors and their receptor in bladder and renal cell carcinoma cell lines. *Cancer Lett* 1996;103:91–97.
- O'Brien TS, Smith K, Cranston D, et al. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. *Br J Urol* 1995;76:311–314.
- O'Brien T, Cranston D, Fuggle S, et al. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. *Cancer Res* 1997;57:136–140.
- Jebar AH, Hurst CD, Tomlinson DC, et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. *Oncogene* 2005;24:5218–5225.
- Mo L, Zheng X, Huang H-Y, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. *J Clin Invest* 2007;117:314–325.
- Zieger K, Dyrskjot L, Wiuf C, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. *Clin Cancer Res* 2005;11:7709–7719.
- Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. *J Clin Oncol* 2006;24:3664–3671.
- Kompier LC, van der Aa MNM, Lurkin I, et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. *J Pathol* 2009;218:104–112.
- Eble JN, Sauter C, Epstein JI, et al. *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*. Lyon, France: IARC Press; 2004.
- Barbisan F, Santinelli A, Mazzucchelli R, et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. *Cancer* 2008;112:636–644.
- di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: Past, present, and future challenges. *Adv Urol* 2012;2012:429213.
- Tomlinson DC, Lamont FR, Shnyder SD, et al. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. *Cancer Res* 2009;69:4613–4620.
- Williams SV, Platt FM, Hurst CD, et al. High-resolution analysis of genomic alteration on chromosome arm 8p in urothelial carcinoma. *Genes Chromosomes Cancer* 2010;49:642–659.
- López-Knowles E, Hernández S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. *Cancer Res* 2006;66:7401–7404.
- Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. *Clin Cancer Res* 2009;15:6008–6017.
- Sjodahl G, Lauss M, Gudjonsson S, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. *PLoS One* 2011;6:e18583.
- Kompier LC, Lurkin I, van der Aa MNM, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. *PLoS One* 2010;5:e13821.
- Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110(alpha) of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. *Proc Natl Acad Sci* 2008;105:2652–2657.
- Ross RL, Askham JM, Knowles MA. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. *Oncogene* 2012;32:768–776.
- Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. *Nat Genet* 2013;45:1464–1469.
- Guo C, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. *Nat Genet* 2013;45:1459–1463.
- Solomon DA, Kim JS, Bondaruk J, et al. Frequent truncating mutations of STAG2 in bladder cancer. *Nat Genet* 2013;45:1428–1430.
- Taylor C, Platt F, Hurst C, et al. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumor grade and stage and inversely related to chromosomal copy number changes. *Hum Mol Genet* 2014;23:1964–1974.
- Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. *Science* 2011;333:1039–1043.
- Cuadrado A, Remeseiro S, Gomez-Lopez G, et al. The specific contributions of cohesin-SAI to cohesion and gene expression: implications for cancer and development. *Cell Cycle* 2012;11:2233–2238.
- Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome. *Eur Urol* 2014;65:360–366.
- Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. *Eur Urol* 2014;65:367–369.
- Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. *Clin Cancer Res* 2003;9:235–242.
- Cairns P, Tokino K, Eby Y, et al. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. *Cancer Res* 1994;54:1422–1424.
- Williamson MP, Elder PA, Shaw ME, et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. *Hum Mol Genet* 1995;4:1569–1577.
- Orlow I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. *J Natl Cancer Inst* 1995;87:1524–1529.
- Aboukassim TO, LaRue H, Lemieux P, et al. Alteration of the PATCHED locus in superficial bladder cancer. *Oncogene* 2003;22:2967–2971.
- McGarvey TW, Maruta Y, Tomaszewski JE, et al. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. *Oncogene* 1998;17:1167–1172.
- Habuchi T, Luscombe M, Elder PA, et al. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. *Genomics* 1998;48:277–288.
- Nishiyama H, Hornigold N, Davies A, et al. A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33. *Genomics* 1999;59:335–338.
- Stadler WM, Steinberg G, Yang X, et al. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. *Clin Cancer Res* 2001;7:1676–1682.
- Knowles MA, Habuchi T, Kennedy W, et al. Mutation Spectrum of the 9q34 Tuberous Sclerosis Gene TSC1 in Transitional Cell Carcinoma of the Bladder. *Cancer Res* 2003;63:7652–7656.
- Pymar LS, Platt FM, Askham JM, et al. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. *Hum Mol Genet* 2008;17:2006–2017.
- Ploussard G, Dubosq F, Soliman H, et al. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer. *Urology* 2010;76:513–518.
- Kruger S, Mahnken A, Kausch I, et al. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. *Eur Urol* 2005;47:463–467.
- Bartolotti R, Cai T, Nesi G, et al. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. *J Surg Res* 2007;143:422–427.
- Carnero A, Hudson JD, Price CM, et al. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. *Nat Cell Biol* 2000;2:148–155.
- Serrano M. The INK4a/ARF locus in murine tumorigenesis. *Carcinogenesis* 2000;21:865–869.
- Nishiyama H, Takahashi T, Takechi Y, et al. Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. *Genes Chromosomes Cancer* 1999;26:171–175.
- Habuchi T, Takahashi T, Kakinuma H, et al. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. *Oncogene* 2001;20:531–537.
- Hurst CD, Platt FM, Taylor CF, et al. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. *Clin Cancer Res* 2012;18:5865–5877.

58. Nord H, Segersten U, Sandgren J, et al. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. *Int J Cancer* 2010;126:1390–1402.
59. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. *Hum Pathol* 2006;37:1568–1576.
60. Fristrup N, Birkenkamp-Demtroder K, Reinert T, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. *Am J Pathol* 2013;182:339–349.
61. Kassouf W, Black PC, Tuziak T, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. *J Urol* 2008;179:353–358.
62. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. *Clin Cancer Res* 2001;7:2440–2447.
63. Kruger S, Weitsch G, Buttner H, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. *Int J Cancer* 2002;102:514–518.
64. Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. *Clin Cancer Res* 2001;7:1957–1962.
65. Forster JA, Paul AB, Harnden P, et al. Expression of NRG1 and its receptors in human bladder cancer. *Br J Cancer* 2011;104:1135–1143.
66. Sauter G, Moch H, Moore D, et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. *Cancer Res* 1993;53:2199–2203.
67. Fleischmann A, Rotzer D, Seiler R, et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. *Eur Urol* 2011;60:350–357.
68. Memon AA, Sorensen BS, Meldgaard P, et al. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. *Br J Cancer* 2006;94:1703–1709.
69. Amsellem-Ouazana D, Bieche I, Tozlu S, et al. Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. *J Urol* 2006;175:1127–1132.
70. Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. *J Urol* 1995;153:919–925.
71. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. *Lancet* 1985;1:366–368.
72. Verdoom B, Kessler E, Flaig T. Targeted therapy in advanced urothelial carcinoma. *Oncology* 2013;27:219–226.
73. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. *Oncogene* 2001;20:1973–1980.
74. Theodorescu D, Cornil I, Sheehan C, et al. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. *Cancer Res* 1991;51:4486–4491.
75. van Rhijn BWC, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. *Cancer Res* 2004;64:1911–1914.
76. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. *Oncogene* 2007;26:5889–5899.
77. Lamont FR, Tomlinson DC, Cooper PA, et al. Small molecule FGF receptor inhibitors block FGF-dependent urothelial carcinoma growth in vitro and in vivo. *Br J Cancer* 2011;104:75–82.
78. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. *J Clin Invest* 2009;119:1216–1229.
79. Miyake M, Ishii M, Koyama N, et al. PD173074, a selective tyrosine kinase inhibitor of FGFR3, inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. *J Pharmacol Exp Ther* 2010;332:795–802.
80. Gust KM, McConkey DJ, Awrey S, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. *Mol Cancer Ther* 2013;12:1245–1254.
81. Herrera-Abreu MT, Pearson A, Campbell J, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3 mutant cancer. *Cancer Discovery* 2013;3:1058–1071.
82. Tomlinson DC, Knowles MA. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. *Am J Pathol* 2010;177:2379–2386.
83. Tomlinson DC, Baxter EW, Loadman PM, et al. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCgamma/COX-2-mediated mechanisms. *PLoS One* 2012;7:e38972.
84. Cheng T, Roth B, Choi W, et al. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. *PLoS One* 2013;8:e57284.
85. Habuchi T, Kinoshita H, Yamada H, et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. *J Natl Cancer Inst* 1994;86:1331–1335.
86. Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, CL1) in urinary bladder cancer. *Oncogene* 2002;21:2476–2483.
87. Schmitz-Drager BJ, Schulz WA, Jurgens B, et al. c-myc in bladder cancer. Clinical findings and analysis of mechanism. *Urol Res* 1997;25:S45–S49.
88. Feber A, Clark J, Goodwin G, et al. Amplification and overexpression of E2F3 in human bladder cancer. *Oncogene* 2004;23:1627–1630.
89. Hurst CD, Tomlinson DC, Williams SV, et al. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. *Oncogene* 2008;27:2716–2727.
90. Oeggerli M, Schraml P, Ruiz C, et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. *Oncogene* 2006;25:6538–6543.
91. Oeggerli M, Tomovska S, Schraml P, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. *Oncogene* 2004;23:5616–5623.
92. Olsson AY, Feber A, Edwards S, et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. *Oncogene* 2007;26:1028–1037.
93. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. *Lancet Oncol* 2005;6:678–686.
94. Schmitz-Drager BJ, Goebell PJ, Ebert T, et al. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? *Eur Urol* 2000;38:691–699;discussion 700.
95. George B, Datar RH, Wu L, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. *J Clin Oncol* 2007;25:5352–5358.
96. Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. *Oncogene* 1991;6:2305–2309.
97. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. *J Natl Cancer Inst* 1992;84:1251–1256.
98. Logothetis CJ, Xu H-J, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. *J Natl Cancer Inst* 1992;84:1256–1261.
99. Xu H, Cairns P, Hu S, et al. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. *Int J Cancer* 1993;53:781–784.
100. Le Frere-Belda MA, Gil Diez de Medina S, Daher A, et al. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status. *Hum Pathol* 2004;35:817–824.
101. Benedict WF, Lerner SP, Zhou J, et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. *Oncogene* 1999;18:1197–1203.
102. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. *J Clin Oncol* 2004;22:1014–1024.
103. Rebouissou S, Herault A, Letouze E, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. *J Pathol* 2012;227:315–324.
104. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. *J Urol* 2007;177:481–487.
105. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRB expression in the progression of bladder transitional cell carcinoma. *J Clin Oncol* 2004;22:1007–1013.
106. Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma. *Br J Cancer* 1999;80:904–908.
107. Cappellen D, Gil Diez de Medina S, Chopin D, et al. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. *Oncogene* 1997;14:3059–3066.
108. Kagan J, Liu J, Stein JD, et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. *Oncogene* 1998;16:909–913.
109. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. *Oncogene* 1998;16:3215–3218.
110. Liu J, Babaian DC, Liebert M, et al. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. *Mol Carcinog* 2000;29:143–150.
111. Wang DS, Rieger-Christ K, Latini JM, et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. *Int J Cancer* 2000;88:620–625.
112. Tsuruta H, Kishimoto H, Sasaki T, et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. *Cancer Res* 2006;66:8389–8396.
113. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. *Genes Dev* 2009;23:675–680.
114. Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. *Nat Genet* 1998;19:348–355.
115. Yoo LI, Liu DW, Le Vu S, et al. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. *Cancer Res* 2006;66:1929–1939.

116. Gildea JJ, Herlevsen M, Harding MA, et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. *Oncogene* 2004;23:6788–6797.
117. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. *Gene Ther* 2003;10:1636–1642.
118. Tanaka M, Koul D, Davies MA, et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. *Oncogene* 2000;19:5406–5412.
119. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. *Science* 2012;338:221.
120. Guo Y, Chekaluk Y, Zhang J, et al. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. *J Pathol* 2013;230:17–27.
121. Griner EM, Theodorescu D. The faces and friends of RhoGDI2. *Cancer Metastasis Rev* 2012;31:519–528.
122. Said N, Smith S, Sanchez-Carbayo M, et al. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. *J Clin Invest* 2011;121:132–147.
123. Said N, Sanchez-Carbayo M, Smith SC, et al. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. *J Clin Invest* 2012;122:1503–1518.
124. Wu Y, Moissoglu K, Wang H, et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. *Proc Natl Acad Sci* 2009;106:5807–5812.
125. Fanning P, Bulovas K, Saini KS, et al. Elevated expression of pp60c-src in low grade human bladder carcinoma. *Cancer Res* 1992;52:1457–1462.
126. Qayyum T, Fyffe G, Duncan M, et al. The interrelationships between Src, Cav-1 and RhoGDI2 in transitional cell carcinoma of the bladder. *Br J Cancer* 2012;106:1187–1195.
127. Thomas S, Overdevest JB, Nitz MD, et al. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. *Cancer Res* 2011;71:832–841.
128. Kastiris E, Murray S, Kyriakou F, et al. Somatic mutations of adenomatous polyposis coli gene and nuclear β -catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. *Int J Cancer* 2009;124:103–108.
129. Zhu X, Kanai Y, Saito A, et al. Aberrant expression of beta-catenin and mutation of exon 3 of the beta-catenin gene in renal and urothelial carcinomas. *Pathol Int* 2000;50:945–952.
130. Kashibuchi K, Tomita K, Schalken JA, et al. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. *Int J Urol* 2007;14:789–794.
131. Baumgart E, Cohen MS, Silva Neto B, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. *Clin Cancer Res* 2007;13:1685–1694.
132. Marsit CJ, Karagas MR, Andrew A, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. *Cancer Res* 2005;65:7081–7085.
133. Urakami S, Shiina H, Enokida H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. *Clin Cancer Res* 2006;12:383–391.
134. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. *Cancer Res* 2010;70:3463–3472.
135. Lindgren D, Sjobahl G, Lauss M, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. *PLoS One* 2012;7:e38863.
136. Zieger K, Wiuf C, Jensen KM, et al. Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer. *BMC Cancer* 2009;9:149.
137. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. *J Clin Oncol* 2013;31:3133–3140.
138. Chekaluk Y, Wu CL, Rosenberg J, et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. *PLoS One* 2013;8:e60927.
139. Eriksson P, Aine M, Sjobahl G, et al. Detailed analysis of focal chromosome arm 1q and 6p amplifications in urothelial carcinoma reveals complex genomic events on 1q, and as a possible auxiliary target on 6p. *PLoS One* 2013;8:e67222.
140. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. *Nat Genet* 2011;43:875–878.
141. Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. *Expert Rev Mol Diagn* 2009;9:259–269.
142. Dudzic E, Goepel JR, Catto JW. Global epigenetic profiling in bladder cancer. *Epigenomics* 2011;3:35–45.
143. Sanchez-Carbayo M. Hypermethylation in bladder cancer: Biological pathways and translational applications. *Tumour Biol* 2012;33:347–361.
144. Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. *Epigenomics* 2011;3:19–34.
145. Kandimalla R, van Tilborg AA, Kompier LC, et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. *Eur Urol* 2012;61:1245–1256.
146. Marsit CJ, Houseman EA, Christensen BC, et al. Identification of methylated genes associated with aggressive bladder cancer. *PLoS One* 2010;5:e12334.
147. Reinert T, Modin C, Castano FM, et al. Comprehensive genome methylation analysis in bladder cancer: Identification and validation of novel methylated genes and application of these as urinary tumor markers. *Clin Cancer Res* 2011;17:5582–5592.
148. Wolff EM, Chihara Y, Pan F, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. *Cancer Res* 2010;70:8169–8178.
149. Lauss M, Aine M, Sjobahl G, et al. DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. *Epigenetics* 2012;7:858–867.
150. Agundez M, Grau L, Palou J, et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours. *Eur Urol* 2011;60:131–140.
151. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. *Int J Cancer* 2011;128:1327–1334.
152. Chung W, Bondaruk J, Jelinek J, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. *Cancer Epidemiol Biomarkers Prev* 2011;20:1483–1491.
153. Zuiverloon TC, Beukers W, van der Keur KA, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. *BJU Int* 2012;109:941–948.
154. Renard I, Joniau S, van Cleynenbreugel B, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. *Eur Urol* 2010;58:96–104.
155. Kandimalla R, Masius R, Beukers W, et al. A 3-Plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. *Clin Cancer Res* 2013;19:4760–4769.
156. Dudzic E, Gogol-Doring A, Cookson V, et al. Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. *PLoS One* 2012;7:e32750.
157. Stransky N, Vallot C, Rey F, et al. Regional copy number-independent regulation of transcription in cancer. *Nat Genet* 2006;38:1386–1396.
158. Vallot C, Stransky N, Bernard-Pierrot I, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. *J Natl Cancer Inst* 2011;103:47–60.
159. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. *Clin Cancer Res* 2005;11:4044–4055.
160. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. *Clin Cancer Res* 2005;11:4415–4429.
161. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. *Cancer Res* 2004;64:4040–4048.
162. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. *Nat Genet* 2003;35:90–96.
163. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. *Clin Cancer Res* 2005;11:4029–4036.
164. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. *J Clin Oncol* 2006;24:778–789.
165. Kim WJ, Kim E-J, Kim S-K, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. *Mol Cancer* 2010;9:3.
166. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. *Oncogene* 2006;25:2685–2696.
167. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. *Clin Cancer Res* 2005;11:2625–2636.
168. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. *Clin Cancer Res* 2007;13:4407–4414.
169. Wang R, Morris DS, Tomlins SA, et al. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. *Cancer Res* 2009;69:3810–3818.
170. Dancik G, Aisner D, Theodorescu D. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. *PLoS Currents* 2011;3:RRN1248.
171. Riester M, Taylor JM, Feifer A, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. *Clin Cancer Res* 2012;18:1323–1333.
172. Dyrskjot L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. *Clin Cancer Res* 2007;13:3545–3551.
173. Takata R, Katagiri T, Kanehira M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. *Cancer Science* 2007;98:113–117.

174. Lauss M, Ringner M, Hoglund M. Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. *Clin Cancer Res* 2010;16:4421–4433.
175. Dyrskjot L, Reinert T, Novoradovsky A, et al. Analysis of molecular intrapatient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. *Br J Cancer* 2012;107:1392–1398.
176. Catto JW, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. *Eur Urol* 2011;59:671–681.
177. Guancial EA, Bellmunt J, Yeh S, et al. The evolving understanding of microRNA in bladder cancer. *Urol Oncol* 2014;32:41.e31–e40.
178. Han Y, Chen J, Zhao X, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. *PLoS One* 2011;6:e18286.
179. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. *Int J Cancer* 2009;124:2236–2242.
180. Dyrskjot L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. *Cancer Res* 2009;69:4851–4860.
181. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. *Urol Oncol* 2007;25:387–392.
182. Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. *Urologic Oncol* 2011;29:794–801, e791.
183. Zhu J, Jiang Z, Gao F, et al. A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer. *PLoS One* 2011;6:e28223.
184. Lamouille S, Subramaniam D, Belloch R, et al. Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. *Curr Opin Cell Biol* 2013;25:200–207.
185. Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. *Br J Cancer* 2010;102:883–891.
186. Ostenfeld MS, Bramsen JB, Lamy P, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. *Oncogene* 2010;29:1073–1084.
187. Villadsen SB, Bramsen JB, Ostenfeld MS, et al. The miR-143/145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. *Br J Cancer* 2012;106:366–374.
188. Bo J, Yang C, Huo K, et al. microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. *FEBS J* 2011;278:786–792.
189. Yoshino H, Chiyomaru T, Enokida H, et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. *Br J Cancer* 2011;104:808–818.
190. Huang L, Luo J, Cai Q, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. *Int J Cancer* 2011;128:1758–1769.
191. Lin Y, Wu J, Chen H, et al. Cyclin-dependent kinase 4 is a novel target in microRNA-195-mediated cell cycle arrest in bladder cancer cells. *FEBS Lett* 2012;586:442–447.
192. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. *Am J Pathol* 2012;180:1808–1815.
193. Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, et al. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. *BMC Med Genomics* 2012;5:40.
194. Ho PL, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells: getting to the root of the problem. *Nat Rev Urol* 2012;9:583–594.
195. van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. *Mol Cancer Res* 2012;10:995–1009.
196. He X, Marchionni L, Hansel DE, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. *Stem Cells* 2009;27:1487–1495.
197. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. *Proc Natl Acad Sci* 2009;106:14016–14021.
198. Su Y, Qiu Q, Zhang X, et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. *Cancer Epidemiol Biomarkers Prev* 2010;19:327–337.
199. Volkmer JP, Sahoo D, Chin RK, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. *Proc Natl Acad Sci* 2012;109:2078–2083.
200. Hafner C, Knuechel R, Zanardo L, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. *Oncogene* 2001;20:4910–4915.
201. Cheng L, Gu J, Ulbright TM, et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. *Cancer* 2002;94:104–110.
202. Kawanishi H, Takahashi T, Ito M, et al. High throughput comparative genomic hybridization array analysis of multifocal urothelial cancers. *Cancer Sci* 2006;97:746–752.
203. Kawanishi H, Takahashi T, Ito M, et al. Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation. *Br J Cancer* 2007;97:260–266.
204. Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: Molecular analysis and clinical implications. *Int J Urol* 2005;12:709–716.
205. Hartmann A, Moser K, Kriegmair M, et al. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. *Am J Pathol* 1999;154:721–727.
206. Obermann EC, Meyer S, Hellge D, et al. Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. *Oncol Rep* 2004;11:745–751.
207. Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. *Cancer Res* 1998;58:5835–5841.
208. van Tilborg AA, de Vries A, de Bont M, et al. Molecular evolution of multiple recurrent cancers of the bladder. *Hum Mol Genet* 2000;9:2973–2980.
209. Letouze E, Allory Y, Bollet MA, et al. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. *Genome Biology* 2010;11:R76.
210. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. *Cancer Res* 2002;62:809–818.
211. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. *Cancer Res* 1994;54:784–788.
212. Hopman AH, Kamps MA, Speel EJ, et al. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. *Am J Pathol* 2002;161:1119–1125.
213. Rosin MP, Cairns P, Epstein JI, et al. Partial alleleotype of carcinoma in situ of the human bladder. *Cancer Res* 1995;55:5213–5216.
214. Lee S, Jeong J, Majewski T, et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. *Proc Natl Acad Sci* 2007;104:13732–13737.
215. Majewski T, Lee S, Jeong J, et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. *Lab Invest* 2008;88:694–721.
216. Sjobahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. *Clin Cancer Res* 2012;18:3377–3386.
217. Sjobahl G, Lovgren K, Lauss M, et al. Toward a molecular pathologic classification of urothelial carcinoma. *Am J Pathol* 2013;183:681–691.
218. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–752.
219. Choi W, Shah JB, Tran M, et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers. *PLoS One* 2012;7:e30206.
220. Wilhelm-Benartzi CS, Koestler DC, Houseman EA, et al. DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. *Carcinogenesis* 2010;31:1972–1976.
221. Juanpere N, Agell L, Lorenzo M, et al. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. *Hum Pathol* 2012;43:1573–1582.
222. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nat Genet* 1999;23:18–20.
223. Bringuier PP, Tamimi J, Schuurings E. Amplification of the chromosome 11q13 region in bladder tumours. *Urol Res* 1994;21:451.
224. Proctor A, Coombs L, Cairns J, et al. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. *Oncogene* 1991;6:789–795.
225. Sgambato A, Migaldi M, Faraglia B, et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. *Int J Cancer* 2002;97:671–678.
226. Lianes P, Orlov I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. *J Natl Cancer Inst* 1994;86:1325–1330.
227. Devlin J, Keen AJ, Knowles MA. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. *Oncogene* 1994;9:2757–2760.
228. Chapman EJ, Hamden P, Chambers P, et al. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. *Clin Cancer Res* 2005;11:5740–5747.
229. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. *Oncogene* 1993;8:1083–1085.
230. Adachi H, Igawa M, Shiina H, et al. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. *J Urol* 2003;170:601–604.
231. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. *Clin Cancer Res* 2005;11:7012.
232. Heidenblad M, Lindgren D, Jonson T, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. *BMC Med Genomics* 2008;1:3.

233. van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. *Cancer Res* 2001;61:1265–1268.
234. Zaharieva BM, Simon R, Diener PA, et al. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. *J Pathol* 2003;201:603–608.
235. Lianes P, Orlov I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer [see comments]. *J Natl Cancer Inst* 1994;86:1325–1330.
236. Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. *Mod Pathol* 2014;27:271–280.
237. Habuchi T, Takahashi R, Yamada H, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. *Cancer Res* 1993;53:3795–3799.
238. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. *Science* 1991;252:706–709.
239. Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. *Cancer Res* 1992;52:1393–1398.
240. Balbas-Martinez C, Rodriguez-Pinilla M, Casanova A, et al. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. *PLoS One* 2013;8:e62483.